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ABSTRACT
Introduction: Antithrombotic therapy carries high
risks for patient safety. Antithrombotics belong to the
top 5 medications involved in potentially preventable
hospital admissions related to medication. To provide a
standard for antithrombotic therapy and stress the
importance of providing optimal care to patients on
antithrombotic therapy, the Landelijke Standaard
Ketenzorg Antistolling (LSKA; Dutch guideline on
integrated antithrombotic care) was drafted. However,
the mere publication of this guideline does not
guarantee its implementation. This may require a
multidisciplinary team effort. Therefore, we designed a
study aiming to determine the influence of hospital-
based antithrombotic stewardship on the effect and
safety of antithrombotic therapy outcomes during and
after hospitalisation.
Methods and analysis: In this study, the effect of
the implementation of a multidisciplinary
antithrombotic team is compared with usual care using
a pre-post study design. The study is performed at the
Erasmus University Medical Center Rotterdam and the
Reinier de Graaf Hospital Delft. Patients who are or will
be treated with antithrombotics are included in the
study. We aim to include 1900 patients, 950 in each
hospital. Primary outcome is the proportion of patients
with a composite end point consisting of ≥1 bleeding
or ≥1 thrombotic event from the beginning of
antithrombotic therapy (or hospitalisation) until
3 months after hospitalisation. Bleeding is defined
according to the International Society of Thrombosis
and Haemostasis (ISTH) classification. A thrombotic
event is defined as any objectively confirmed arterial or
venous thrombosis, including acute myocardial
infarction or stroke for arterial thrombosis and deep
venous thrombosis or pulmonary embolism or venous
thrombosis. An economic evaluation is performed to
determine whether the implementation of the
multidisciplinary antithrombotic team will be
cost-effective.
Ethics and dissemination: This protocol was
approved by the Medical Ethical Committee of the
Erasmus University Medical Center. The findings of the
study will be disseminated through peer-reviewed
journals and presented at relevant conferences.
Trial registration number: NTR4887; pre-results.
INTRODUCTION
Antithrombotic therapy carries high risks for
patient safety.1–3 The Dutch HARM (Hospital
Admissions Related to Medication) study4
showed that 5.6% of all unplanned hospitalisa-
tions in the Netherlands were drug-related
and that 46% of these were potentially pre-
ventable. Antithrombotics belong to the top 5
medications involved in potentially preventable
hospital admissions related to medication.1–4
In response to the HARM study, a multidis-
ciplinary guideline was drafted to provide a
standard for antithrombotic therapy and to
stress the importance of providing optimal
care to patients on antithrombotic therapy:
Strengths and limitations of this study
▪ This will be the first study to determine the
effect of a multidisciplinary antithrombotic team
in two Dutch hospitals.
▪ Data will be collected in two different hospitals,
accounting for the differences between a univer-
sity medical centre and a general teaching
hospital.
▪ Improvements may already have been implemen-
ted during the preimplementation period because
of the nationwide attention to the Landelijke
Standaard Ketenzorg Antistolling (LSKA).
▪ The data collection method may be hampered by
recall bias (bleeding and thrombotic events) and
response bias (questionnaires).
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the ‘Landelijke Standaard Ketenzorg Antistolling’
(LSKA; Dutch guideline on integrated antithrombotic
care).5
However, the mere publication of this guideline does
not guarantee its implementation. A parallel can be
drawn with an active policy on reduction of antibiotic
resistance: all hospitals are involved in such policies, but
recently antibiotic stewardship was only recently pro-
posed in order to further enhance such policies.
Multidisciplinary antibiotic teams (A-teams) have been
shown to be useful for optimisation of therapy.6
Analogous to the A-teams, multidisciplinary antithrom-
botic teams (in Dutch ‘Stollingsteam’ or S-team) focus-
ing on antithrombotics can be made responsible for
LSKA implementation, can provide expertise to support
the care of inpatients and outpatients alike, ensure
adequate transitioning of patients from the inpatient to
the outpatient setting, and improve patient education.
Studies on the implementation and (cost-)effective-
ness of a multidisciplinary antithrombotic team are
scarce. Antithrombotic services in US hospitals are
described mainly as pharmacist-led antithrombotic ser-
vices that are predominantly aimed at therapy with war-
farin.7 This differs from the Dutch situation, where
treatment with VKA (vitamin K antagonists) is mostly
carried out by medical doctors in thrombosis services,
whereas patients treated with other anticoagulants, such
as DOACs (direct oral anticoagulants), are not yet fol-
lowed systematically. In one survey sent to members of
the America College of Pharmacists practice and
research networks for cardiology, critical care and
general internal medicine, only 4 of 25 responding
member centres indicated that their antithrombotic
service was multidisciplinary.7 Padron and Miyares8
describe an expanded antithrombotic stewardship,
including both DOAC treatment and facilitating care
after hospital discharge. It concerned a US single-centre
pharmacist-directed stewardship. Only a small retrospect-
ive control group (n=12) was included in the study. A
total of 409 patients on antithrombotics were monitored.
Interventions consisted of changes to a more appropri-
ate antithrombotic therapy according to guidelines and
dosing corrections. The length of hospital stay was
reduced by 1.5 days and cost-savings were $270.320
($661 per patient) in 1.5 years.8 Tedders and colleagues
evaluated the impact of an inpatient, pharmacist-led
dabigatran management protocol. Almost half of the
176 adult patients (46%) required pharmacist interven-
tion related to dabigatran management during hospital
admission, particularly for dosing corrections and transi-
tioning between dabigatran and alternative anticoagulants.9
Discharge patient education and promoting patient know-
ledge with regard to antithrombotic therapy is described
in a few studies, but again mostly on warfarin.10 11
Given this paucity of evidence on the effect of antith-
rombotic stewardship, the proposed study aims to deter-
mine the inﬂuence of hospital-based multidisciplinary
antithrombotic stewardship on the effect and safety of
antithrombotic therapy outcomes during and after hos-
pitalisation, and the cost-effectiveness of such a multidis-
ciplinary team effort. The null hypothesis is that a
multidisciplinary antithrombotic team does not improve
the effect and safety of antithrombotic therapy during
and after hospitalisation.
METHODS AND ANALYSIS
Study design
A prospective non-randomised before-and-after study,
with the intervention being a quality improvement as is
mandated by the national guideline LSKA, is performed.
The effect between a usual care group (preimplementa-
tion measurement) and an intervention group (postim-
plementation measurement) will be compared. First,
patients are included during 9 months in the usual care
group (preimplementation phase with 3 months’
follow-up). Second, the intervention is implemented
(implementation phase of 3 months). Finally, patients
are included during 9 months in the intervention group
(postimplementation phase with 3 months’ follow-up,
see ﬁgure 1 for ﬂow chart).
Study setting
The study will be performed at the Erasmus University
Medical Center (Erasmus MC) and the Reinier de Graaf
Hospital. The Erasmus MC is a 1320-bed university
medical centre based in Rotterdam. The Reinier de
Graaf Hospital is a general teaching hospital located in
Delft, the Netherlands with 590 beds. The study will be
carried out from 2015 to 2017.
Study population
Patients who are or will be treated with antithrombotics in
the Erasmus MC or in the Reinier de Graaf Hospital are
eligible for inclusion in the study. In the Reinier de Graaf
Hospital, a clinical rule is used to identify the patients, and
in the Erasmus MC an email is generated when an antith-
rombotic is prescribed to the patient. Patients are consid-
ered eligible for inclusion if they are using one or more
medicines that are listed in tables 1 and 2. Exclusion cri-
teria are the following: (1) no informed consent from the
patient (or the parents/guardian of the patient), (2)
Figure 1 Phases during the
study.
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patients with hospital stays of <24 hours, (3) patients
admitted to the intensive care unit, (4) patients treated
with low molecular weight heparins only for thrombosis
prophylaxis, (5) patients enrolled in a clinical trial of
antithrombotic therapy, (6) patients treated with phyto-
menadione for the prevention and treatment of vitamin
K deﬁciency, (7) patients treated during hospitalisation
with a single dose of an anticoagulant medicine. Only
the patient’s ﬁrst hospital admission is included in the
study period (readmission is an end point).
Study procedures
Usual care
During the preimplementation phase, usual care in
both hospitals is provided to patients.
Medication surveillance at admission: The pharmacy soft-
ware automatically checks the prescribed medication in
relation to the medication record that is available within
the pharmacy system and automatically generates medi-
cation surveillance and signals in case of interactions,
overdose, double medication and contraindications.
The automatically generated medication signals
(including signals on antithrombotics) are routinely
checked during hospital admission by the hospital
pharmacist but no structured medication review or
pharmacotherapy review is performed.
Patient counselling: At present, resident physicians and
nurses are involved in patient instructions on pharmaco-
therapy. The time spent on medication-related patient
instructions is rather limited or is not performed at all.
The knowledge necessary for providing adequate
instructions is often insufﬁcient in residents and nurses.
Medication reconciliation at discharge: The resident phys-
ician prints a prescription or a medication list from the
hospital system. The prescription or medication list is
sent to the community pharmacist.
The hospital pharmacy is not involved in the dis-
charge of a patient. The medication list provides little or
no information on changes in the pharmacotherapy and
the reasons for these changes.
Consultation for professionals inside and outside the hospital:
In the current situation, hospital residents and/or hae-
matologists are consulted inside the hospital, and hos-
pital pharmacists for speciﬁc pharmacotherapeutic
issues on antithrombotics. Consultation by professionals
outside the hospital is mainly directed towards the
haematologists.
Intervention
The intervention consists of the implementation of the
multidisciplinary antithrombotic team, which is a quality
improvement dictated by the LSKA (Dutch guideline on
integrated antithrombotic care). The team in the
Erasmus MC will consist of a specialised thrombosis
nurse as case manager, a haematologist, a paediatric
haematologist, a medical leader regional thrombotic
service (responsible for outpatient management of VKA
treatment), a hospital pharmacist/clinical pharmacolo-
gist, a cardiologist, an anaesthesiologist, a pulmonologist,
a neurologist, a surgeon and a quality ofﬁcer. In the
Reinier de Graaf Hospital, the team will consist of a spe-
cialised thrombosis nurse as case manager, a haematolo-
gist, a medical leader regional thrombotic service, a
hospital pharmacist/clinical pharmacologist, a cardiolo-
gist, an anaesthesiologist and a neurologist. A pulmonol-
ogist, dermatologist, clinical chemist, paediatrician,
emergency physician and (orthopaedic) surgeon may be
added to the team when necessary.
Medication surveillance at admission: During hospital
admission, a structured medication review will be per-
formed daily by the hospital pharmacist/clinical
pharmacologist focused on optimising treatment with
antithrombotics. The pharmacotherapy review focuses
Table 2 Haemostatic agents*
Group of haemostatic
agents (ATC code)
Haemostatic agents (ATC
code)
Antifibrinolytics (B02AA) Tranexamic acid (B02AA02)
Vitamin K (B02BA) Phytomenadione (B02BA01)
Fibrinogen (B02BB) Fibrinogen, human (B02BB01)
Coagulation factor
concentrates (B02BD)
Prothrombin complex
concentrate (B02BD01)
Activated prothrombin complex
concentrate (B02BD03)
Eptacog alfa (activated)
(B02BD08)
Antidotes (V03AB) Protamine (V03AB14)
*New haemostatic agents, including specific antagonist of Xa
inhibitors or dabigatran, which may enter the market during our
study, will also be included in the study when they are introduced
in the hospital.
Table 1 Antithrombotics*
Group of antithrombotics
(ATC code)
Antithrombotics
(ATC code)
Vitamin K antagonists
(B01AA)
Phenprocoumon
(B01AA04)
Acenoucoumarol
(B01AA07)
Heparin group (B01AB) Heparin (B01AB01)
Antithrombin III
(B01AB02)
Dalteparin (B01AB04)
Enoxaparin (B01AB05)
Nadroparin (B01AB06)
Danaparoide (B01AB09)
Tinzaparine (B01AB10)
Direct thrombin inhibitors
(B01AE)
Bivaluridin (B01AE06)
Dabigatran etexilate
(B01AE07)
Direct factor Xa inhibitors
(B01AF)
Rivaroxaban (B01AF01)
Apixaban (B01AF02)
Other anticoagulants (B01AX) Fondaparinux (B01AX05)
*New antithrombotics entering the market are also included in the
study when they are introduced in the hospital.
ATC, anatomical therapeutic chemical.
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on dosing (eg, in relation to decreased renal function),
double medication, drug–drug interactions, contraindi-
cations and perioperative bridging of anticoagulants.
Patient counselling: The purpose of patient empower-
ment is to provide information and education to patients
with the aim of giving the patient more control and
responsibility in their own care. Patients need to learn
about antithrombotic therapy and how to safely care for
it on a daily basis.
Medication reconciliation at discharge: At discharge, medi-
cation reconciliation is performed by the specialised
thrombosis nurse and the hospital pharmacy.
Discrepancies with the preadmission medication are
checked using the medication history of the community
pharmacy, the appropriateness of the pharmacotherapy
is examined, the pharmacotherapy is checked and it is
ensured that there is a proper transition to either the
thrombotic service or the general practitioner, and to
the community pharmacist.
Consultation for professionals inside and outside the hospital:
To further support the cooperation between primary
care (thrombotic service, the general practitioner and
the community pharmacist) and hospital care, consult-
ation is offered by professionals in the multidisciplinary
antithrombotic teams.
Drafting of local guidelines: The purpose of drafting
local guidelines is to ensure that there is a uniform
policy on antithrombotic therapy in the hospital.
Educating physicians, nurses and hospital pharmacists: To
increase the knowledge of antithrombotic therapy
among physicians, nurses and hospital pharmacists,
hospital-wide education is given. The education will
assist in providing a uniform antithrombotic policy
within the hospital.
Data collection
Outcome measures
The primary outcome of this study is the proportion of
patients with a composite end point consisting of ≥1
bleeding (major bleeding and non-major bleeding) or
≥1 thrombotic event from the beginning of antithrom-
botic therapy (or hospitalisation) until 3 months after
hospitalisation. Bleeding is deﬁned according to the
International Society of Thrombosis and Haemostasis
(ISTH) deﬁnitions.
As secondary outcomes, patient-related outcomes and
costs will be determined among others. All secondary
outcomes are listed below.
The hospital information system is used for collection
of the outcome parameters during hospitalisation. For
collection of the postdischarge outcomes, validated ques-
tionnaires are used. Three months after hospitalisation,
the questionnaires are sent to the patient. The patient’s
general practitioner is asked for bleeding or thrombotic
events and readmission when the questionnaires are not
returned after one reminder.
For each included patient, data are collected in an
electronic case report form (CRF); see table 3 for
detailed information.12 13 Data are collected during the
preimplementation and postimplementation periods.
The following parameters are registered:
▸ Major bleeding and non-major bleeding events
during and 3 months after hospitalisation: the bleed-
ing events are evaluated and classiﬁed by an inde-
pendent assessment committee consisting of two
experts in the ﬁeld, using the ISTH deﬁnitions of
bleeding (table 4).14 15
▸ Severity and location of bleeding complication: the
WHO bleeding scale is used to deﬁne the location of
the bleeding (oral and nasal, skin, soft tissue, muscu-
loskeletal, gastrointestinal, genitourinary, pulmonary,
body cavity, central nervous system, invasive sites and
haemodynamic instability).16 The ISTH deﬁnitions
(table 4) are used to determine the severity of the
bleeding event.
▸ Thrombotic events during and 3 months after hospi-
talisation: the thrombotic events are evaluated and
classiﬁed by an independent assessment committee
consisting of two experts in the ﬁeld. A thrombotic
event is deﬁned as any objectively conﬁrmed arterial
or venous thrombosis, including acute myocardial
infarction or stroke for arterial thrombosis and deep
venous thrombosis or pulmonary embolism or venous
thrombosis. The deﬁnitions of terms are listed in
table 5.17–20
▸ Severity and location of thrombotic complication: the
locations of thrombotic events are listed in table 5.
The severity of the thrombotic complication is classi-
ﬁed as fatal or non-fatal.
▸ Patient data: these are extracted from the medical
records of the hospital information system and
include date of birth, gender, weight on the ﬁrst day
of hospitalisation, medication use during hospitalisa-
tion, laboratory values, (co)morbidities classiﬁed
according to García-Olmos et al21 and any surgery or
diagnosis during hospitalisation.
▸ Readmissions within 3 months after discharge.
▸ The quality of life is measured by the EuroQol EQ-5D
(age 16 and older) or EQ-5D-Y (age 4–15) question-
naire.22–24
▸ Patients are asked to ﬁll out a questionnaire about
their adherence to anticoagulation treatment
(Medication Adherence Rating Scale, MARS).25–28
▸ The patient satisfaction of the anticoagulation therapy
is measured by the visual analogue satisfaction scale.29
▸ Adherence by the doctors to the hospital protocol:
information from the medical record of the hospital
information system is used to verify the adherence by
the doctors to the hospital protocol. To determine
the adherence to the hospital protocol, the following
items are checked: dosing (eg, in relation to
decreased renal function, age, body weight), peri-
operative bridging of anticoagulants, double medica-
tion and contraindications.
▸ All-cause mortality: the hospital information system is
used to register the date of death and the cause of
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Table 3 Data collection: content of CRF
Part Data content
Patient data Patient ID
Date of birth*
Gender*
Weight on the first day of hospitalisation*
Community pharmacist*†
Reason for hospitalisation*
Reason for exclusion
(Co)morbidity*
Day of hospitalisation*
Hospital discharge date*
Any surgery (coded with Verrichtingen code)12 or diagnosis during hospitalisation*
Study outcomes Bleeding (major bleeding and non-major bleeding) event(s) during hospitalisation*
Bleeding (major bleeding and non-major bleeding) event(s) within 3 months after hospitalisation‡
Severity of bleeding complication
Location of bleeding complication
Thrombotic event(s) during hospitalisation*
Thrombotic event(s) within 3 months after hospitalisation‡
Severity of thrombotic complication*
Location of thrombotic complication
Date of each readmission in the following 3 months after the first hospitalisation*‡
The reason for readmission‡
Quality of life (3 months after discharge):†
▸ Age 0–3: no EQ-5D-Y available
▸ Age 4–7: EQ-5D-Yproxy V.1
▸ Age 8–11: EQ-5D-Y or EQ-5D-Y proxy
▸ V.1
▸ Age 12–15: EQ-5D-Y or EQ-5D
▸ Age 16 and older: EQ-5D
Adherence by the patient to the therapy; MARS5 (3 months after discharge)†
Patient satisfaction of the antithrombotic therapy; VAS satisfaction scale (3 months after discharge)†
Adherence to the hospital protocol
Percentage of TTR of vitamin K antagonists during hospitalisation and as an outpatient during 3 months’
follow-up*
All-cause mortality*§
Healthcare costs*
Clinical chemistry
data
Laboratory values and the date of determination*§
▸ INR
▸ APTT
▸ PT
▸ dTT
▸ Hb
▸ Anti-Xa
▸ Creatinine
▸ HT
▸ Erythrocytes
▸ Thrombocytes
▸ eGFR
▸ Weight
(Available clinical chemistry data are collected from 3 months before inclusion until 3 months after
hospitalisation)
Medication data Medication use during hospitalisation (coded with ATC code)13 *
Use of antidotes: tranexamic acid, phytomenadione, fibrinogen, prothrombin complex concentrate, activated
prothrombin complex concentrate, eptacog alfa (activated) and protamine (coded with ATC code)13 *
Use of blood products: blood transfusion and other blood products*
Overview of medication use 3 months before hospitalisation (coded with ATC code)13§
Overview of medication use 3 months after hospitalisation (coded with ATC code)13§
*Obtained from the medical record of the hospital information system.
†Obtained from the patient by using a questionnaire.
‡Obtained by sending a small questionnaire asking for visits to the general practitioner or hospital because of a bleeding or thrombotic event
within 3 months after hospitalisation.
§Obtained from the community pharmacist and the thrombosis service.
Anti-Xa, antifactor Xa; APTT, activated partial thromboplastin time; CRF, case report form; dTT, diluted thrombin time; eGFR, estimated
glomerular filtration rate; Hb, haemoglobin; HT, haematocrit; INR, international normalised ratio; MARS, Medication Adherence Rating Scale;
PT, prothrombin time; TTR, time in therapeutic range; VAS, visual analogue scale.
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death. The patient’s general practitioner is asked for
the date of death and the cause of death 3 months
after hospitalisation.
▸ Percentage of time in therapeutic range (TTR) of
patients on vitamin K treatment during
hospitalisation and as an outpatient during 3 months’
follow-up: the international normalised ratio (INR)
data during hospitalisation from the electronic
medical record are collected by a specialised depart-
ment in both hospitals. The INR data 3 months after
Table 4 ISTH definitions of bleeding in patients.
Type of bleeding Definition of bleeding
Major bleeding in non-surgical
patients14
1. Fatal bleeding, and/or
2. Symptomatic bleeding in a critical area or organ, such as intracranial, intraspinal,
intraocular, retroperitoneal, intra-articular or pericardial, or intramuscular with
compartment syndrome, and/or
3. Bleeding causing a fall in haemoglobin level of 20 g/L (1.24 mmol/L) or more, or leading
to transfusion of two or more units of whole blood or red cells
Major bleeding in surgical
patients15
1. Fatal bleeding, and/or
2. Bleeding that is symptomatic and occurs in a critical area or organ, such as intracranial,
intraspinal, intraocular, retroperitoneal, pericardial, in a non-operated joint, or
intramuscular with compartment syndrome, assessed in consultation with the surgeon,
and/or
3. Extrasurgical site bleeding causing a fall in haemoglobin level of 20 g/L (1.24 mmol/L) or
more, or leading to transfusion of two or more units of whole blood or red cells, with
temporal association within 24–48 hours to the bleeding, and/or
4. Surgical site bleeding that requires a second intervention (open arthroscopic,
endovascular) or a haemarthrosis of sufficient size as to interfere with rehabilitation by
delaying mobilisation or delayed wound healing, resulting in prolonged hospitalisation or
a deep wound infection, and/or
5. Surgical site bleeding that is unexpected and prolonged and/or sufficiently large to cause
haemodynamic instability, as assessed by the surgeon. There should be an associate
fall in haemoglobin level of at least 20 g/L (1.24 mmol/L), or transfusion, indicated by the
bleeding, of at least two units of whole blood or red cells, with temporal association
within 24 hours to the bleeding.
Non-major bleeding All bleeding events that do not meet the ISTH criteria according to which major bleeding is
defined
ISTH, International Society of Thrombosis and Haemostasis.
Table 5 Definition of thrombotic events
Arterial or venous thrombosis Definition of the arterial or venous thrombosis
Acute myocardial infarction17 Detection of a rise and/or fall of cardiac biomarker values (preferably cTn) with at
least one value above the 99th centile URL and with at least one of the following:
▸ Symptoms of ischaemia
▸ New or presumed new significant ST–T changes or new LBBB
▸ Development of pathological Q waves in the ECG
▸ Imaging evidence of new loss of viable myocardium or new regional wall motion
abnormality
▸ Identification of an intracoronary thrombus by angiography or autopsy
Stroke18 An embolic, thrombotic or stroke with motor, sensory or cognitive dysfunction (such
as hemiplegia, hemiparesis, aphasia, sensory deficit, impaired memory) that
persisted for 24 or more hours
Deep venous thrombosis19 An acute vascular occlusion of an extremity or organ, documented by means of
imaging, surgery or autopsy
Pulmonary embolism20 The presence of a blood clot in a pulmonary artery with subsequent obstruction of
blood supply to the lung parenchyma or if the patient had a ventilation-perfusion scan
interpreted as high probability of pulmonary embolism or a positive result on spiral
CT, transoesophageal echocardiography, pulmonary arteriography or CT
angiography
Any objectively determined arterial or
venous thrombus
Non-cerebral, non-cardiac arterial thrombotic or embolic events
cTn, cardiac troponin; LBBB, left bundle branch block; ST–T, ST segment–T wave; URL, upper reference limit.
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hospitalisation are obtained from the thrombosis
service. TTR is a way of summarising INR control
over time. A TTR of 70–80% is desirable,30 and
according to European guidelines, TTR should be
above 70%.31 TTR was calculated according to FR
Roosendaal’s algorithm with linear interpolation.32
▸ Medication use 3 months before and 3 months after
hospitalisation: medication records of the community
pharmacy can be consulted through a link in the hos-
pital information system for patients who are within
the catchment area of the hospital. If a community
pharmacist is not connected to the hospital informa-
tion system, the hospital pharmacy will obtain a faxed
medication list from the community pharmacist.
Economic evaluation
The aim of the economic evaluation is to determine
whether the implementation of the S-team will be cost-
effective. All costs will be calculated from time to start
with antithrombotics (or hospitalisation) until 3 months
after hospitalisation. Economic analysis will be per-
formed from a healthcare system perspective taking all
healthcare costs into account. The costs of the S-team
(labour costs and costs for bleeding/thrombotic events
(including use of antidotes) will be calculated. All
in-hospital (eg, hospitalisation, medication, bleeding
and thrombotic events) and outpatient healthcare costs
(eg, general practitioner) will be assessed.
Actual medical costs will be calculated by multiplying
the volume of healthcare use by corresponding unit
prices.
For the intervention, the full cost price will be calcu-
lated following the microcosting method,33 which is
based on a detailed inventory and measurement of all
resources used. Therefore, costs for all separate actions
and time used by all individual healthcare professionals
will be calculated for the S-team intervention. For the
other healthcare costs, standard cost prices will be used
as published in the Dutch guidelines for economic
evaluation studies.34
To measure the economic impact of the multidiscip-
linary team approach, cost-effectiveness will be assessed
by calculating the incremental cost-effectiveness ratio,
deﬁned here as the costs for the intervention (minus
savings) divided by the difference in the proportion of
patients with a composite end point consisting of ≥1
bleeding (major bleeding and non-major bleeding) or
≥1 thrombotic event during and 3 months after hospital-
isation between the intervention and usual care.
Data monitoring
Data are collected on questionnaires (hard copy) and
on a CRF using OpenClinica. OpenClinica is an open
source clinical trial software for Electronic Data Capture
(EDC) Clinical Data Management (CDM). Data entry
errors are minimised by using multiple choice options
and ﬁxed data ﬁelds. In the OpenClinica system, each
user is assigned a user type. The data manager submits
the data and the monitor checks the conformity of data
in CRFs, helping to ensure that the study is complete,
accurate and veriﬁable. OpenClinica validates the ﬁle
format and performs validity checking for the data.
Access to OpenClinica is secured by a password.
Sample size calculation
Annual bleeding rates are 2–3% depending on the type
of antithrombotics,35 36 but in everyday practice it seems
that this rate is at least 10%.37 Conservatively, we will
presume a rate of 5%. Annual thrombotic event rates
are about 3%.36 We assume that this is the rate we could
achieve with the S-team and that the rate is 4% in the
preimplementation period. This results in a composite
rate of 9% and we expect to decrease this to a composite
rate of 5.5%. With a type 1 error of 0.05, power of 80%,
the required sample size will be 917 patients in the pre-
implementation phase and 917 patients in the postim-
plementation phase. In order to account for drop-outs,
1900 patients will be included. This calculation is based
on annual event rates, although our follow-up is only
3 months. However, since our study is on hospitalised
patients (and shortly after hospitalisation), we assume
that this presents a period of instability for the patient,
leading to relatively high event rates.
Based on the current admission numbers of patients
meeting the inclusion criteria, we estimate a total of 30
eligible patients per day in the Erasmus MC. In the
Reinier de Graaf Hospital, this is an average of 15
patients per day. Owing to the limited availability of
study personnel, it is possible to recruit three patients
per day per hospital. A random number generator will
be used to select these three patients. With this inclusion
rate, we expect to have included the necessary number
of patients in a 9 months preimplementation period and
in a 9 months postimplementation period.
Data analysis
For the primary end point (the proportion of patients
with a composite end point consisting of ≥1 bleeding
(major bleeding and non-major bleeding) or ≥1 throm-
botic event from the beginning of antithrombotic
therapy (or hospitalisation) until 3 months after hospi-
talisation), interrupted time series analysis is used for
data analysis. Baseline data are collected over 3-month
separate measurements during a 9-month period, as will
be the postimplementation data. The study design thus
meets the criteria for a robust interrupted time series
analysis, that is three periods of data points preimple-
mentation and postimplementation, each consisting of
at least 30 patients.38–40 The primary outcome will be
compared using univariate and multivariate logistic
regression. Subanalyses will be performed for each type
of antithrombotic and for hospital type in relation to
bleeding and thrombotic events. In addition, in-hospital
and postdischarge events will be analysed separately.
Linear or logistic regression is performed for the
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secondary outcomes (frequency of bleeding events, fre-
quency of thrombotic events, severity of bleeding com-
plications, length of hospital stay, readmissions, quality
of life, adherence by the patient to the therapy, patient
satisfaction with antithrombotic therapy, adherence to
the hospital protocol, healthcare costs, all-cause mortal-
ity and the percentage of time in a therapeutic range of
VKA). To assess whether differences between preimple-
mentation and postimplementation periods may be
explained by other factors, that is, differences in patient
characteristics for the two periods, will also be compared
with the use of the appropriate test (t-test,
Mann-Whitney U test or Pearson’s χ2 test).
ETHICS AND DISSEMINATION
Ethical approval
This study is registered in the Dutch Trial Registry for
clinical trials (record number NTR4887) on 3
November 2014.41 All participants will provide written
and informed consent and can withdraw from the study
at any time.
Dissemination
The ﬁndings of the study will be disseminated through
peer-reviewed journals and presented at relevant
conferences.
DISCUSSION
Antithrombotic therapy carries high risks for patient
safety, mainly bleeding episodes. Multidisciplinary teams
have been proposed to improve the safety of antithrom-
botic therapy. However, most antithrombotic services are
described mainly as pharmacist-led antithrombotic ser-
vices in US hospitals that are predominantly aimed at
warfarin dosing, which differs from the Dutch situation.
In this study, we want to determine the effect of a multi-
disciplinary antithrombotic team on the frequency of a
composite end point consisting of bleeding and throm-
botic events in two Dutch hospitals. The design of this
study has several strengths. First, we have gained experi-
ence with the data collection procedure due to a previ-
ous pilot project at the Reinier de Graaf Hospital.
Therefore, we were able to optimise study procedures
such as collection of the outcome parameters. Second,
we will investigate the effect of the team in two different
hospitals, at the Erasmus MC and the Reinier de Graaf
Hospital, accounting for the differences between a uni-
versity medical centre and a general teaching hospital.
This will enhance the generalisability. Third, a substan-
tial number of patients are to be included. We anticipate
having little problems in recruiting patients in order to
ensure sufﬁcient statistical power which should enable
us to measure the primary outcome. A fourth strength
of this study is the patient empowerment intervention.
Empowerment of the patient increases their autonomy
and involvement in their care and treatment. Fifth, we
are also conducting a cost-effectiveness assessment.
Finally, the multidisciplinary antithrombotic team is
offering consultation for professionals both inside and
outside the hospital.
This study also has some limitations. First, studies
using questionnaires for collection of several secondary
outcomes may suffer from response bias. This will be
minimised as much as possible by contacting the
patients by telephone when the questionnaires are not
returned within 2 weeks. Second, despite the fact that
this is a multicentre study, only two hospitals are
included. Third, in obtaining the patient data, we are
dependent on the information in the medical records.
Fourth, introducing recall bias for minor bleeding and
thrombotic events. Fifth, the sample size calculation is
based on annual event rates, although our follow-up is
only 3 months. This is justiﬁed by the assumption that
the period during and shortly after hospitalisation repre-
sents a period of instability for the patient, leading to a
relatively high frequency of events. Yet we have no litera-
ture data to support our assumption, so the sample size
may prove to be too small. Finally, it is a prospective non-
randomised before-and-after study, without a retrospec-
tive control group. Improvements may already have been
implemented during the preimplementation period
because of the nationwide attention to the LSKA.
However, by time series analysis, we mean to adjust for
this effect.
In conclusion, the main objective of this study is to
assess the effectiveness of a multidisciplinary antithrom-
botic team with the aim of reducing the frequency of a
composite end point consisting of bleeding and throm-
botic events. If such a team proves to be effective, imple-
mentation in hospitals will be recommended.
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